Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2025
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms
22 April 2025 - Real-world evidence is increasingly used and accepted by health technology assessment (HTA) bodies as supportive evidence ...
Posted by Michael Wonder on 03 Apr 2025
Real-world evidence to support health technology assessment and payer decision making: is it now or never?
31 March 2025 - The aim of this policy article is twofold: (i) to provide a summary and update of recent ...
Posted by Michael Wonder on 28 Dec 2024
What price is society willing to pay for new drugs?
12 December 2024 - The purpose of England's NHS is to improve the health and wellbeing of the nation through provision ...
Posted by Michael Wonder on 18 Dec 2024
What is NICE’s severity modifier?
15 December 2024 - A guide to the severity modifier and how it is leading to more positive recommendations overall from ...
Posted by Michael Wonder on 16 Dec 2024
Should NICE’s cost effectiveness thresholds change?
13 December 2024 - We explore the on-going debate around NICE’s cost effectiveness thresholds and what the future holds. ...
Posted by Michael Wonder on 06 Dec 2024
Does NICE’s “severity modifier” for assessing diseases need to change?
22 November 2024 - Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in ...
Posted by Michael Wonder on 29 Apr 2023
Prioritising patients in negotiations over drug pricing
14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...
Posted by Michael Wonder on 04 Feb 2023
NICE’s new methods reflect society’s values
4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...
Posted by Michael Wonder on 07 Nov 2022
Can we use existing guidance to support the development of robust real world evidence for health technology assessment/payer decision-making?
2 November 2022 - Advances in the digitisation of health systems and expedited regulatory approvals of innovative treatments have led to ...
Posted by Michael Wonder on 08 Sep 2022
Esketamine: NICE’s appraisal was unfair, appeal panel rules
8 September 2022 - The decision by the UK National Institute for Health and Care Excellence not to recommend esketamine ...
Posted by Michael Wonder on 06 Sep 2022
ICR criticises NICE rejection of olaparib for advanced prostate cancer
6 September 2022 - The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not ...
Posted by Michael Wonder on 17 Aug 2022
UK will not buy Evusheld owing to “insufficient data” on protection, Government says
15 August 2022 - The UK Government has said that it will not procure the COVID-19 drug Evusheld—a combination of ...
Posted by Michael Wonder on 11 Jul 2022
The (harsh) reality of real-world data external comparators for health technology assessment
8 July 2022 - We read with great interest the recently published article by Patel et al. and commend the authors ...
Posted by Michael Wonder on 25 May 2022
Target trial emulation for transparent and robust estimation of treatment effects for health technology assessment using real world data: opportunities and challenges
25 May 2022 - Evidence about the relative effects of new treatments is typically collected in randomised controlled trials. ...
Posted by Michael Wonder on 09 May 2022
Choices that fail health and wellbeing
5 May 2022 - NICE's expert group RAPID C-19, set up to ‘to ensure safe and timely patient access to treatments ...